Leuprolide vs Triptorelin
How they differ
- FDA status, the same for both (FDA-approved). Leuprolide: FDA-approved as Lupron, Eligard, Vobrig and other leuprolide products.1,2,3,4,5,6 Triptorelin: FDA-approved as Trelstar for advanced prostate cancer.7,8
- Kinds of studies cited. Leuprolide: limited human data. Triptorelin: large randomized human trials. How these labels are assigned
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | Leuprolide | Triptorelin |
|---|---|---|
| What it is | A GnRH agonist. The Eligard label describes leuprolide acetate as a synthetic nonapeptide analogue of GnRH that is more potent than the natural hormone.1 | A synthetic decapeptide agonist analogue of GnRH, the hypothalamic hormone that controls the pituitary’s reproductive hormones, according to the label.7 |
| FDA status | FDA-approved FDA-approved as Lupron, Eligard, Vobrig and other leuprolide products1,2,3,4,5,6 FDA-approved. Drugs@FDA lists Lupron with an original approval date of April 9, 1985, and Eligard with one of January 23, 2002, among many leuprolide applications. The cited Eligard label has no boxed warning.1,2,4 | FDA-approved FDA-approved as Trelstar for advanced prostate cancer7,8 FDA-approved. Drugs@FDA lists Trelstar with an original approval date of June 15, 2000, for advanced prostate cancer. The cited label has no boxed warning.7,8 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.9 | Not among the six peptides the policy lists.9 |
| FDA compounding safety-risk page | Not addressed in this profile’s sources. | Not addressed in this profile’s sources. |
| Kinds of studies cited |
|
|
| Records collected | 117 ClinicalTrials.gov records and 48 PubMed records collected | 30 ClinicalTrials.gov records and 30 PubMed records collected |
| Area of study | ||
| Latest dated events |
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1ELIGARD (leuprolide acetate) injection, suspension, extended release · SPL version 19 · published 2026-05-11 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 2Drugs@FDA application NDA019010 · original submission status AP · 1985-04-09 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 3Drugs@FDA application NDA019732 · original submission status AP · 1989-01-26 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 4Drugs@FDA application NDA021343 · original submission status AP · 2002-01-23 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 5Vobrig (leuprolide acetate): NDA 213225 approval letter, August 26, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 6Drugs@FDA application NDA213225 · original submission status AP · 2026-08-26 · dataset 2026-11-13 ↗
Drugs@FDA via openFDA · Official source · Source checked November 15, 2026
- 7TRELSTAR (triptorelin pamoate) kit · SPL version 20 · published 2026-07-10 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 8Drugs@FDA: TRELSTAR (triptorelin pamoate), NDA 020715 · original approval June 15, 2000 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 9HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 10Drugs@FDA application NDA213150 · original submission status AP · 2020-05-01 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026